PF
GLMD icon

Phoenix Financial’s Galmed Pharmaceuticals GLMD Stock Holding History

Phoenix Financial’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-101
Closed -$480K – 389
2020
Q3 		$480K Buy
101
+8
+9% +$52.3K 0.02% 232
2020
Q2 		$611K Buy
93
+41
+79% +$277K 0.03% 231
2020
Q1 		$253K Buy
52
+39
+300% +$297K 0.01% 279
2019
Q4 		$105K Sell
13
-5
-28% -$34.4K ﹤0.01% 193
2019
Q3 		$115K Buy
+18
New +$144K 0.01% 187

Other funds holding GLMD

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

Phoenix Financial's GLMD Position: Q4 2020 in Review

Phoenix Financial sold out of Galmed Pharmaceuticals (GLMD) in Q4 2020, closing a stake of 101 shares — an estimated $480K sold.

Phoenix Financial first reported a position in GLMD in Q3 2019 and held it in 5 quarters. The position peaked at $611K in Q2 2020. 18 funds tracked by Wall St. Rank hold GLMD as of Q4 2020.

  • Phoenix Financial reported no remaining Galmed Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Phoenix Financial sold 101 Galmed Pharmaceuticals shares in Q4 2020, an estimated $480K.
  • Phoenix Financial first reported a position in Galmed Pharmaceuticals in Q3 2019 and held it in 5 quarters.
  • Phoenix Financial's Galmed Pharmaceuticals position peaked at $611K in Q2 2020.
  • 18 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2020.

Based on Phoenix Financial's 13F filing for Q4 2020, filed 11 Feb 2021.